AtriCure, Inc.

ATRC Healthcare Medical Instruments & Supplies

AtriCure, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $534.5 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 12.8%, EPS grew 238.5%, free cash flow fell 2.79% and total debt fell 4.43%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

56.09 1.69 −2.92%
Market cap
$2.9B
P/E
259×
Fwd P/E
591×
Dividend yield
—
F-score
7/9
Altman Z
7.31
Beneish M
−2.91
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 62.64 0.00 0.00 0.00 0.00
Piotroski F-Score
4 4 5 2 4 4 3 6 4 7
P/S ratio
3.91 3.42 5.17 5.29 11.35 11.42 6.21 4.10 3.08 3.53
Altman Z-Score
2.87 2.72 5.72 2.07 4.53 14.67 9.33 6.78 5.81 7.31
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 103.31
Altman Z″-Score (non-manufacturers)
(0.12) (0.56) 2.33 (0.12) 1.87 4.47 3.18 3.17 2.76 3.44
Beneish M-Score
(2.88) (2.73) (2.70) (2.28) (2.85) (1.75) (2.24) (2.60) (2.80) (2.91)
P/Operating CF
797.49 391.48 1,058.95 (346.28) 593.10 10,410.10 44,586.56 405.86 245.93 94.32
P/B ratio
3.60 3.71 4.18 4.94 5.69 6.48 4.49 3.51 3.11 3.84
Price to Tangible BV
54.90 116.27 10.99 0.00 47.46 15.21 11.23 9.77 8.46 9.03
EV/Sales
3.89 3.45 4.81 5.26 10.49 11.25 6.06 3.96 3.00 3.40
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 20.41 0.00 0.00 0.00 157.03
EV/Operating CF
(39.86) (67.43) (232.30) (76.77) (109.07) (223.94) (90.39) 352.28 114.31 31.67
EV/FCF
(26.42) (39.35) (93.38) (43.42) (86.24) (131.13) (51.29) (42.11) (47.73) 99.30
Quick Ratio
2.26 1.80 3.72 2.20 5.44 2.69 2.81 2.55 2.49 2.87
Current Ratio
2.97 2.58 4.34 2.87 6.24 3.47 3.69 3.57 3.65 3.96
Net Debt/EBITDA
0.24 (0.19) 8.75 0.34 5.41 (0.31) 1.71 7.13 2.94 (9.13)
Debt/Assets
14.07% 13.98% 14.70% 13.20% 9.26% 11.63% 12.20% 9.87% 10.15% 9.46%
Debt/Equity
0.23 0.23 0.21 0.30 0.16 0.15 0.16 0.13 0.13 0.13
Asset Turnover
0.56 0.64 0.65 0.50 0.32 0.41 0.55 0.67 0.76 0.85
Operating CF/Net income
0.45 0.33 0.20 0.45 0.41 (0.27) 0.48 (0.15) (0.27) (5.01)
Capex/Depreciation
(0.80) (0.68) (0.70) (1.38) (0.47) (0.10) (1.23) (0.75) (0.59) (0.43)
Interest Coverage
(17.29) (11.03) (3.72) (8.06) (9.05) 11.23 (8.56) (3.85) (6.25) (1.61)
ROE
(18.78%) (16.32%) (10.30%) (14.17%) (14.60%) 11.20% (9.88%) (6.60%) (9.64%) (2.40%)
ROA
(12.13%) (9.88%) (6.77%) (7.70%) (7.57%) 7.55% (7.74%) (5.08%) (7.31%) (1.81%)
ROIC
(11.92%) (9.51%) (6.03%) (8.66%) (11.80%) 7.91% (6.55%) (4.28%) (6.25%) (1.53%)
Return on Tangible Assets
(38.37%) (34.00%) (13.08%) (27.96%) (16.84%) 29.35% (23.75%) (13.00%) (18.93%) (4.09%)
Average Days of Receivables
49.64 48.22 45.61 44.35 40.91 43.94 47.17 48.00 47.33 45.51
Research and Development Expense of Revenue
23.10% 19.54% 17.22% 17.86% 20.85% 17.68% 17.35% 18.51% 20.67% 18.56%
Selling, General and Administrative Expense of Revenue
68.61% 66.96% 64.24% 72.42% 73.03% 74.60% 70.00% 63.40% 62.62% 58.19%
Intangible Assets out of Total Assets
0.57 0.58 0.43 0.65 0.51 0.45 0.47 0.49 0.48 0.43
Share Based Compensation of Revenue
7.54% 8.37% 8.18% 7.79% 10.96% 10.24% 8.71% 8.95% 8.68% 8.36%
Graham Net Nets
(0.04) (0.04) 0.06 (0.14) 0.00 0.02 0.04 0.07 0.08 0.08
Graham Number
0.00 0.00 0.00 0.00 0.00 16.37 0.00 0.00 0.00 0.00
Earnings Yield
(5.47%) (4.49%) (2.06%) (2.86%) (2.07%) 1.60% (2.25%) (1.87%) (3.11%) (0.60%)
Free Cash Flow Yield
(3.76%) (2.56%) (0.99%) (2.29%) (1.07%) (0.75%) (1.90%) (2.29%) (2.04%) 0.97%
Revenue per Share
4.91 5.39 5.92 6.14 4.90 6.09 7.22 8.62 9.91 11.19
Operating CF per Share
(0.48) (0.28) (0.12) (0.42) (0.47) (0.31) (0.48) 0.10 0.26 1.20
Capex per Share
(0.24) (0.20) (0.18) (0.32) (0.12) (0.22) (0.37) (0.26) (0.24) (0.19)
Free Cash Flow per Share
(0.72) (0.47) (0.30) (0.74) (0.60) (0.52) (0.85) (0.16) 0.02 1.01
Cash per Share
1.39 1.06 3.65 2.18 5.80 2.64 2.65 2.96 2.61 3.51
Shareholders Equity per Share
5.33 4.98 7.32 6.58 9.79 10.73 9.99 10.07 9.82 10.30
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
5.33 4.98 7.32 6.58 9.79 10.73 9.99 10.07 9.82 10.30
Free Cash Flow
(22.81) (15.33) (10.38) (27.95) (25.13) (23.53) (39.02) (7.51) 0.77 48.28
Working Capital
56.89 50.36 134.46 93.24 257.60 139.63 156.82 191.68 194.40 241.00
Capital Expenditures
(7.69) (6.38) (6.20) (12.14) (5.26) (9.75) (16.88) (12.00) (11.43) (9.05)
Net Current Asset Value
(22.26) (24.28) 67.30 (167.38) 4.59 64.52 86.52 118.48 119.47 160.27
EV/EBIT
0.00 0.00 0.00 0.00 0.00 55.90 0.00 0.00 0.00 0.00
Capex to Sales
0.05 0.04 0.03 0.05 0.03 0.04 0.05 0.03 0.02 0.02
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 56.76 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.32 0.33 0.33 0.27 0.40 3.06 0.35 0.38 0.46 0.54
Cash ROIC
(9.07%) (6.58%) (2.43%) (6.94%) (3.48%) (3.49%) (6.01%) (1.13%) 0.12% 6.69%
Accounts Receivable Turnover
7.66 7.91 8.35 8.67 8.07 9.77 8.73 8.39 8.25 8.42
Accounts Payable Turnover
3.76 4.20 4.94 4.92 4.13 4.37 4.39 4.19 4.50 5.31
Inventory Turnover
2.49 2.42 2.43 2.33 1.78 1.85 1.99 1.74 1.64 1.74
Average Days of Payables
88.52 93.45 64.68 90.22 81.24 99.14 86.01 100.98 77.57 69.07
Days of Inventory on Hand
146.47 168.78 150.55 177.54 223.42 207.71 198.54 250.64 233.46 214.20
Average Receivables
20.25 22.09 24.14 26.62 25.60 28.08 37.86 47.60 56.42 63.50
Average Payables
11.71 11.55 11.05 12.30 13.84 15.67 19.25 23.63 26.19 25.17
Average Inventory
17.66 20.06 22.47 25.95 32.22 37.00 42.45 56.91 71.62 76.91
Average Assets
274.76 272.06 312.23 457.32 636.21 664.93 600.38 599.69 611.63 631.75
Average Common Equity
177.56 164.80 205.27 248.36 329.87 448.08 470.26 461.46 463.57 476.45

Fold the line items

Columns are period end dates